Skip to main content

Table 2 Treatments and outcomes of patients

From: Impact of bronchoalveolar lavage lymphocytosis on the effects of anti-inflammatory therapy in idiopathic non-specific interstitial pneumonia, idiopathic pleuroparenchymal fibroelastosis, and unclassifiable idiopathic interstitial pneumonia

 

Anti-inflammatory drugs

P value

n

No (n = 63)

Yes (n = 123)

Corticosteroid monotherapy

0 (0.0)

39 (31.7)

< 0.001

186

Combined with immunosuppressants

0 (0.0)

84 (68.3)

< 0.001

186

Cyclosporine A

0 (0.0)

56 (45.5)

Tacrolimus

0 (0.0)

5 (4.1)

Cyclophosphamide

0 (0.0)

13 (10.6)

Azathioprine

0 (0.0)

10 (8.1)

Anti-fibrotic drugs*

20 (31.7)

30 (24.4)

0.370

186

 Pirfenidone

14 (22.2)

23 (18.7)

 Nintedanib

5 (7.9)

7 (5.7)

One-year changes

 ΔLDH (IU/L)

− 15.1 ± 84.7

− 16.8 ± 192.3

0.934

168

 ΔKL-6 (U/mL)

− 347 ± 1234

− 602 ± 1691

0.270

169

 ΔSP-D (ng/mL)

16.4 ± 121.1

− 168.5 ± 558.1

0.004

131

 ΔFVC % predicted (%)

− 2.9 ± 10.9

3.1 ± 19.7

0.016

156

 ΔDLCO % predicted (%)

− 1.9 ± 25.6

5.5 ± 20.8

0.113

132

One-year outcomes

 Improvement**

7 (14.9)

41 (37.6)

0.015

156

 Stable

26 (55.3)

44 (40.4)

 Worsening***

14 (29.8)

24 (22.0)

Death during observation period

11 (17.5)

31 (25.2)

0.270

186

  1. *One patient with missing data on which of the anti-fibrotic drugs was used
  2. **Improvement was defined as a ≥ 10% increase in %FVC or a ≥ 15% increase in %DLCO
  3. ***Worsening was defined as a > 10% decrease in %FVC or a > 15% decrease in %DLCO
  4. DLCO diffusion capacity for carbon monoxide, FVC forced vital capacity, KL-6 Krebs von den Lungen-6, LDH lactate dehydrogenase, SP-D surfactant protein D